Kidney bean

Wicked Kitchen Launches First 100% Animal-Free Concession at Minneapolis' Target Center in Partnership with NBA's Timberwolves

Retrieved on: 
Monday, October 17, 2022

MINNEAPOLIS, Oct. 17, 2022 /PRNewswire/ -- Wicked Kitchen, a 100% plant-based, flavor-forward global food brand announces its foray into serving sports teams and fans in the U.S. with its first plant-based concession stand debuting at the Target Center in partnership with the Minnesota Timberwolves in its home court of Minneapolis.

Key Points: 
  • "It's an honor to provide our hometown team with a Wicked experience that fans will love and crave," said Pete Speranza, CEO, Wicked Kitchen.
  • Chef Chad Sarno, chief culinary officer and co-founder at Wicked Kitchen and a highly regarded pioneer of plant-based cuisine, will oversee the menu at the Wicked Kitchen concession.
  • "Wicked Kitchen is a wonderful addition to our concession lineup at Target Center, providing delicious and approachable plant-based options for our fans," said Ryan Tanke, chief operating officer, Minnesota Timberwolves and Lynx.
  • We are so excited to introduce Wicked Kitchen to Timberwolves fans this season."

Global End Stage Renal Disease Market Report (2022 to 2030) - Growing Prevalence of Diabetes and Hypertension is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 20, 2022

The global end stage renal disease market size is anticipated to reach USD 261.64 billion by 2030, registering a CAGR of 12.9% over the forecast period.

Key Points: 
  • The global end stage renal disease market size is anticipated to reach USD 261.64 billion by 2030, registering a CAGR of 12.9% over the forecast period.
  • Chronic Kidney Disease (CKD) is one of the major causes of increasing kidney failure rates among patients.
  • Technological advancements in the treatment of renal failure are another factor expediting the market growth for ESRD.
  • End Stage Renal Disease Market Variables, Trends & Scope

US's First Contract Manufacturer Offering Private Label Jellybean Supplements, SMP Nutra, Launches 3 New Jellybean Formulas

Retrieved on: 
Wednesday, August 31, 2022

They have formulated a white label biotin jellybean formula that they are offering to all who are interested.

Key Points: 
  • They have formulated a white label biotin jellybean formula that they are offering to all who are interested.
  • SMP Nutra is one of the few US-based facilities that can create highly-demanded nutraceutical jellybean formulas.
  • SMP Nutra is currently the only US-based contract manufacturer that offers these types of supplements to any brand owner.
  • About SMP Nutra: SMP Nutra is a leading turnkey supplement manufacturer based in the USA.

End Stage Renal Disease Global Market Report 2022: Value to Reach $18.06 Billion by 2027 at a CAGR of 16.63% - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 7, 2022

The "End Stage Renal Disease Market Research Report by Treatment (Dialysis and Transplantation), Diagnosis, End-User, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "End Stage Renal Disease Market Research Report by Treatment (Dialysis and Transplantation), Diagnosis, End-User, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
  • The United States End Stage Renal Disease Market size was estimated at USD 7,173.99 million in 2021, USD 8,638.02 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 16.63% to reach USD 18,063.62 million by 2027.
  • This research report categorizes the End Stage Renal Disease to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Treatment, the market was studied across Dialysis and Transplantation.
  • Based on Diagnosis, the market was studied across Blood tests, Imaging tests, Kidney sample removal for testing, and Urine tests.

It's Not Ice Cream, It's Better: Wicked Kitchen Elevates National Ice Cream Month with Innovative Plant-Based Ice Creams

Retrieved on: 
Wednesday, June 15, 2022

MINNEAPOLIS, June 15, 2022 /PRNewswire/ -- With demand for plant-based ice creams and novelties higher than ever, Wicked Kitchen, a 100% plant-based, flavor-forward global food brand, celebrates National Ice Cream Month this July by offering one winner a year's supply of premium Wicked Kitchen ice creams. Starring the lupini bean, the ice creams are considered a gamechanger in the category, and are the first to market in the U.S.

Key Points: 
  • Customers can purchase any Wicked Kitchen ice cream pint or novelty, take a photo or video that shows the ice cream in a bowl, on a cone or in a recipe and then post and share, with Wicked Kitchen tagged.
  • All posts in the month of July will be entered to win a free year of Wicked Kitchen ice cream and a Wicked goodie box complete with an autographed copy of The Wicked Healthy Cookbook by Derek & Chad Sarno.
  • "Our lupini bean-based ice creams, sticks and cones offer incredible texture and flavor and are second to none."
  • Operating in the U.S., UK and Finland, Wicked Kitchen provides convenient meal solutions and increased availability of plant-based foods.

Calliditas Therapeutics Launches an Online Patient Platform

Retrieved on: 
Saturday, May 14, 2022

STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.

Key Points: 
  • STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.
  • Bonnie Schneider, Director and Co-Founder of the IgA Nephropathy Foundation of America commented, IgA nephropathy is a complicated disease that can leave individuals with many unanswered questions.
  • With the launch of IgAN Connect, I am grateful that individuals will have even more resources to embark on this journey.
  • Calliditas common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

Spookley the Square Pumpkin Celebrates Easter With New Shorts on Disney Junior and DisneyNOW

Retrieved on: 
Wednesday, April 6, 2022

WILTON, Conn., April 6, 2022 /PRNewswire-PRWeb/ -- LINK TO PHOTOS

Key Points: 
  • begins airing in rotation April 8 on Disney Junior and will be available that same day on Disney Junior YouTube and in DisneyNOW.
  • The Spookley Easter Show will debut April 8 in DisneyNOW and on the Official Spookley YouTube channel.
  • For more information about Spookley the Square Pumpkin and Holiday Hill Farm, please visit the official Spookley website ( spookley.com ) and follow Spookley on Facebook ( facebook.com/Spookley/ ) and Instagram ( @spookleythesquarepumpkin ).
  • Holiday Hill Enterprises is the production company behind literary-based franchise Spookley the Square Pumpkin and Holiday Hill Farm.

Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea

Retrieved on: 
Monday, March 14, 2022

SHANGHAI, March 13, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that it has entered into a license agreement with Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) to develop and commercialize NEFECON for the treatment of primary IgA nephropathy (IgAN) in South Korea, expanding its license in addition to rights held in Greater China and Singapore. The deal signals the Company's latest efforts to further enhance its international commercial footprint.

Key Points: 
  • "South Korea's sophisticated healthcare model enables innovative medicines such as NEFECON to have a higher potential likelihood of healthcare coverage once approved.
  • Under the terms of the agreement, Calliditas receives an initial upfront payment of USD$3 million at signing of the agreement.
  • In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON in Mainland China, Hong Kong, Macau, Taiwan and Singapore.
  • The agreement was extended in March 2022 to include South Korea as part of Everest Medicine's territories.

Organic Superfood Pioneer Navitas Organics Roots Itself in Superfoods with Purpose™ - A Commitment to Creating a Healthier World through Regenerative Organic Farming and Plant-Based Lifestyles

Retrieved on: 
Friday, March 4, 2022

NOVATO, Calif., March 4, 2022 /PRNewswire/ -- Navitas Organics , the organic superfood pioneer, has announced the rollout of Superfoods with Purpose ,a credo that underscores the company's ongoingcommitment to creating a healthier world through regenerative organic farming and plant-based lifestyles.

Key Points: 
  • NOVATO, Calif., March 4, 2022 /PRNewswire/ -- Navitas Organics , the organic superfood pioneer, has announced the rollout of Superfoods with Purpose ,a credo that underscores the company's ongoingcommitment to creating a healthier world through regenerative organic farming and plant-based lifestyles.
  • Superfoods with Purpose encompasses who we are and our commitment to uphold our mission."
  • We are committed to creating a healthier world through regenerative organic farming and plant-forward lifestyles.
  • We hope you join us in our Superfoods with Purpose commitment by connecting with us on navitasorganics.com , and on Instagram , Facebook , and Twitter .

Experimental Compound Counters Diabetic Complications

Retrieved on: 
Wednesday, November 24, 2021

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- An experimental compound reduced complications of type 1 and type 2 diabetes in mice not by lowering blood sugar but by countering its consequences: cell death, inflammation, and organ damage.

Key Points: 
  • NEW YORK, Nov. 24, 2021 /PRNewswire/ -- An experimental compound reduced complications of type 1 and type 2 diabetes in mice not by lowering blood sugar but by countering its consequences: cell death, inflammation, and organ damage.
  • The results revolve around the body's immune system, which recognizes and destroys invading bacteria and viruses.
  • Experiments in human cells and mouse models found that the lead study compound, RAGE229, significantly reduced short- and long-term complications of diabetes.
  • The team next incorporated the RAGE229 molecule into mouse chow because dietary intake could better measure its ability to reverse long-term complications like diabetic wounds.